187 related articles for article (PubMed ID: 35513117)
1. The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys.
Huskinson SL; Platt DM; Zamarripa CA; Dunaway K; Brasfield M; Prisinzano TE; Blough BE; Freeman KB
Pharmacol Biochem Behav; 2022 Jun; 217():173394. PubMed ID: 35513117
[TBL] [Abstract][Full Text] [Related]
2. Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys.
Huskinson SL; Platt DM; Brasfield M; Follett ME; Prisinzano TE; Blough BE; Freeman KB
Psychopharmacology (Berl); 2020 Jul; 237(7):2075-2087. PubMed ID: 32372348
[TBL] [Abstract][Full Text] [Related]
3. Contingent administration of typical and biased kappa opioid agonists reduces cocaine and oxycodone choice in a drug vs. food choice procedure in male rhesus monkeys.
Zamarripa CA; Huskinson SL; Townsend EA; Prisinzano TE; Blough BE; Rowlett JK; Freeman KB
Psychopharmacology (Berl); 2024 Feb; 241(2):305-314. PubMed ID: 37870564
[TBL] [Abstract][Full Text] [Related]
4. The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats.
Zamarripa CA; Pareek T; Schrock HM; Prisinzano TE; Blough BE; Sufka KJ; Freeman KB
Psychopharmacology (Berl); 2021 Dec; 238(12):3463-3476. PubMed ID: 34430992
[TBL] [Abstract][Full Text] [Related]
5. Quantification of observable behaviors following oral administration of oxycodone and nalfurafine in male rhesus monkeys.
Huskinson SL; Platt DM; Smith ZR; Doyle WS; Zamarripa CA; Dunaway K; Prisinzano TE; Freeman KB
Drug Alcohol Depend; 2023 Nov; 252():110953. PubMed ID: 37734282
[TBL] [Abstract][Full Text] [Related]
6. Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.
Zamarripa CA; Naylor JE; Huskinson SL; Townsend EA; Prisinzano TE; Freeman KB
Psychopharmacology (Berl); 2020 May; 237(5):1471-1480. PubMed ID: 32006048
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
[TBL] [Abstract][Full Text] [Related]
8. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
9. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.
Liu JJ; Chiu YT; DiMattio KM; Chen C; Huang P; Gentile TA; Muschamp JW; Cowan A; Mann M; Liu-Chen LY
Neuropsychopharmacology; 2019 Apr; 44(5):939-949. PubMed ID: 30082888
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
Dunn A; Windisch K; Ben-Ezra A; Pikus P; Morochnik M; Erazo J; Reed B; Kreek MJ
Psychopharmacology (Berl); 2020 Aug; 237(8):2405-2418. PubMed ID: 32435819
[TBL] [Abstract][Full Text] [Related]
11. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between
Cao D; Huang P; Chiu YT; Chen C; Wang H; Li M; Zheng Y; Ehlert FJ; Zhang Y; Liu-Chen LY
ACS Chem Neurosci; 2020 Oct; 11(19):3036-3050. PubMed ID: 32897695
[TBL] [Abstract][Full Text] [Related]
13. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
Ko MC; Husbands SM
J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
[TBL] [Abstract][Full Text] [Related]
14. The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone's conditioned rewarding effects in male rats.
Zamarripa CA; Patel TR; Williams BC; Pareek T; Schrock HM; Prisinzano TE; Freeman KB
Behav Pharmacol; 2020 Dec; 31(8):792-797. PubMed ID: 32804774
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.
Zhou Y; Freeman K; Setola V; Cao D; Kaski S; Kreek MJ; Liu-Chen LY
Handb Exp Pharmacol; 2022; 271():137-162. PubMed ID: 33834276
[TBL] [Abstract][Full Text] [Related]
16. Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.
Townsend EA
Psychopharmacology (Berl); 2021 Apr; 238(4):1017-1028. PubMed ID: 33404739
[TBL] [Abstract][Full Text] [Related]
17. Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats.
Townsend EA; Naylor JE; Negus SS; Edwards SR; Qureshi HN; McLendon HW; McCurdy CR; Kapanda CN; do Carmo JM; da Silva FS; Hall JE; Sufka KJ; Freeman KB
Psychopharmacology (Berl); 2017 Sep; 234(17):2597-2605. PubMed ID: 28567699
[TBL] [Abstract][Full Text] [Related]
18. Involvement of GRK2 in modulating nalfurafine-induced reduction of excessive alcohol drinking in mice.
Zhou Y; Liang Y
Neurosci Lett; 2021 Aug; 760():136092. PubMed ID: 34197905
[TBL] [Abstract][Full Text] [Related]
19. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.
Brust TF; Morgenweck J; Kim SA; Rose JH; Locke JL; Schmid CL; Zhou L; Stahl EL; Cameron MD; Scarry SM; Aubé J; Jones SR; Martin TJ; Bohn LM
Sci Signal; 2016 Nov; 9(456):ra117. PubMed ID: 27899527
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of biased signaling at the kappa opioid receptor.
El Daibani A; Paggi JM; Kim K; Laloudakis YD; Popov P; Bernhard SM; Krumm BE; Olsen RHJ; Diberto J; Carroll FI; Katritch V; Wünsch B; Dror RO; Che T
Nat Commun; 2023 Mar; 14(1):1338. PubMed ID: 36906681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
